How to Rapidly Lower Cortisol, Fix Mitochondria and Sleep Like a Baby (TONIGHT)

DeLauer frames this as a deliberate pattern interrupt before the day’s stressors accumulate. Instead of starting the day near the ‘red line’ of the fight-or-flight threshold, breath work creates a buffer. Over time, this can reduce overall cortisol load and improve HRV. The practice is portable and requires no equipment.

DeLauer frames TTS as a cheap, real-world proxy for autonomic nervous system status. If you’re lying in bed for 90+ minutes with racing thoughts, you are in a fight-or-flight loop. Each night of poor sleep compounds recovery deficits and increases endotoxins and amyloid waste. By tracking TTS, you can objectively see how interventions (breath work, vagal stimulation, light therapy) affect your nervous system. He emphasizes that people don’t have unlimited sleep time; long TTS eats into actual recovery time.

DeLauer contrasts this with light therapy: electrical stimulation is a large, short-term impact (time-to-sleep drops dramatically), while red light treatment is smaller but additive over time. Because the effect fades, people need to use it regularly, but it can break the cycle of bedtime rumination. He mentions that in his studies, a single treatment achieved this TTS reduction, which underscores the speed of vagal nerve stimulation. It’s positioned as an accessible tool for those who can’t quickly meditate themselves out of a stress spike.

DeLauer describes two tiers of effect: 1) the mitochondrial ATP surge of 60–80% over 10–12 hours, with the higher end seen in metabolically compromised individuals; 2) the cardiovascular benefit from nitric oxide release, which expands vessels and improves oxygen delivery. He emphasizes that this is not a quick fix — it stacks over weeks and months, unlike the transient vagal stimulation. The synergy between improved oxygen delivery and cellular oxygen utilization is key. He also notes that the gut-brain axis benefits only fully materialize when the vagus nerve is open; otherwise, the brain neurotransmitter lift (BDNF, serotonin, dopamine) may not occur.

DeLauer’s caution emerged from observing that some people have negative reactions to methylene blue because their cellular ‘engine’ is compromised. He uses an analogy: you wouldn’t redline a car engine with a cracked block. The two-month preparatory period gives the body time to repair phospholipid bilayers via supplementation, diet, and training. He notes that this advice is congruent with the broader principle of fixing metabolic foundations before adding mitochondrial stimulants.

DeLauer described how his team did breath work during a prior visit, and he has since incorporated it every morning. The goal is to ‘set the tone for the day’ from a foundation of parasympathetic dominance rather than starting near the ‘red line’ of autonomic arousal. He observes that this makes it harder to trigger a full fight-or-flight response later. The practice is not a one-off tool but a preventive daily habit that lowers the baseline stress threshold.

When they peeled back the data, they discovered that the non-responders shared a common trait: their vagus nerve was ‘just locked up — there's no traffic going anywhere.’ In a fight-or-flight state, the vagus nerve acts like a jammed highway, so the signals from a healthy gut cannot reach the brain. Only after adding protocols like breath work and vagus nerve stimulation did these users start seeing the neurotransmitter increases from gut treatment. This finding underscores that gut interventions alone are insufficient if the vagal pathway is blocked; behavioral or electrical vagal stimulation is a necessary first step to ‘unlock the highway’ and allow the gut-brain communication to flow. It reframes the gut-brain axis as a two-step process requiring both a well-treated gut and an open vagal conduit.

DeLauer points to emerging evidence that plaque may be a protective response to an underlying problem: microvascular dysfunction. He explains that when the gut’s tight junctions loosen over years, endotoxins leak into the body and reach the brain, causing a form of metabolic disruption labeled type 3 diabetes. This chronic microvascular damage impairs oxygen and nutrient delivery, leading to cognitive decline. The medical community is now observing that removing plaque pharmacologically does not improve cognition, reinforcing that the real issue lies upstream. DeLauer’s team is exploring how improving microvascular performance via light therapy and gut healing could be a more leveraged intervention.

The vagus nerve branches both inside and outside the ear. By placing electrodes in or around the ear, researchers can capture electrical signals from the temporal lobe — the brain region most associated with the autonomic nervous system — and reconstruct what a full EEG would show. DeLauer describes this as a breakthrough that could let individuals, not just labs, continuously monitor their autonomic state. It could provide a real-time ‘video’ rather than a snapshot, enabling people to see how daily behaviors affect stress and recovery, and adjust protocols accordingly.

DeLauer explains that methylene blue works by increasing electron transport efficiency in mitochondria. However, if a person’s cellular and mitochondrial membranes are compromised — due to metabolic dysfunction, phospholipid imbalance, or chronic inflammation — ramping up mitochondrial activity creates excessive oxidative stress without the structural integrity to handle it. He advises people to assess their metabolic health first and, if in doubt, spend a couple of months supporting phospholipid bilayers with a supplement like phosphatidylcholine before considering methylene blue. His larger rule: ‘build the engine, maintain the engine, then rev it up.’